相关实验视频
Updated: Jun 19, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
双抗血小板治疗与单抗血小板治疗在非轻微缺血性中风患者:一个元分析
Izabela Orlandi Môro1, Gabriel Marinheiro2, Marianna Leite3
1Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória, Vitória ES, Brazil.
Arquivos de neuro-psiquiatria
|February 24, 2025
概括
对于非轻微缺血性中风患者,双重抗血小板治疗 (DAPT) 与单次抗血小板治疗 (SAPT) 相比,在复发性中风,出血或死亡率上没有显著差异. 这一发现对于指导中风护理治疗决策至关重要.
科学领域:
- 神经学 神经学
- 心血管医学 心血管医学
- 临床试验 临床试验
背景情况:
- 缺血性中风患者面临复发,恶化和死亡的高风险.
- 双重抗血小板治疗 (DAPT) 的好处已在轻微的缺血性中风中确立,但对非轻微病例的证据有限.
研究的目的:
- 评估DAPT与非轻微缺血性中风患者的单抗血小板治疗 (SAPT) 的相对益处和风险.
主要方法:
- 在PubMed,Embase和Cochrane图书馆数据库中进行了系统的搜索,直到2024年4月.
- 包括随机临床试验和观察性研究,比较DAPT和SAPT在非轻微缺血性中风 (NIHSS得分≥4) 中.
主要成果:
- 对6项研究 (12,480名患者) 的分析显示,对于复发性中风 (RR 0.91),缺血性中风 (RR 0.89),或出血性中风 (RR 1.23),DAPT和SAPT之间没有显著差异.
- 在两个治疗组之间,主要出血事件 (RR 0.87) 和全因死亡率 (RR 0.72) 也没有显著差异.
- 基线NIHSS得分从4到15不等,这表明包括的研究中中风严重程度的范围.
结论:
- 在DAPT和SAPT之间没有观察到关于复发性中风,缺血性中风,出血性中风,严重出血或非轻微缺血性中风患者的整体死亡率的显著差异.
- 目前的证据表明,在这个患者群体中,DAPT和SAPT的疗效和安全性概况相似.
相关概念视频
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
455
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
455